An observational study in Infertility, Infertility (IVF Patients) and Infertility Assisted Reproductive Technology, sponsored by Stella Maris Women and Children Hospital. Completed at 1 site in Indonesia. Open to female participants aged 21 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Stella Maris Women and Children Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to evaluate the relationship between luteinizing hormone (LH)-guided recombinant LH supplementation and IVF outcomes in women aged 21-45 years undergoing their first IVF/ICSI cycle using a gonadotropin-releasing hormone (GnRH) antagonist protocol.
The main questions it aims to answer are:
Researchers will compare two groups of women:
Group A (LH-Guided Supplementation): Women with serum LH levels below 1.2 mIU/mL on menstrual cycle day 2 or stimulation day 5 (corresponding to menstrual cycle day 6) who received recombinant LH supplementation at 75 IU/day until ovulation triggering.
Group B (No LH Supplementation): Women with serum LH levels of 1.2 mIU/mL or higher at both assessments who underwent standard ovarian stimulation without recombinant LH supplementation.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
This study's enrollment of 395 is above the median of 200 across 592 observational studies indexed under Infertility.
Browse Infertility studies →Stella Maris Women and Children Hospital is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population consisted of women receiving fertility treatment at Halim Fertility Center, Medan, Indonesia. Participants were identified retrospectively from the center's medical records of IVF/ICSI treatment cycles conducted between January and December 2023. The study evaluated patients who underwent ovarian stimulation using a GnRH antagonist protocol as part of routine clinical care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort included 154 women undergoing their first IVF/ICSI cycle using a GnRH antagonist protocol who had serum luteinizing hormone (LH) levels below 1.2 mIU/mL on menstrual cycle day 2 or stimulation day 5 (corresponding to menstrual cycle day 6). As part of routine clinical care, these patients received recombinant LH supplementation at a dose of 75 IU/day, starting when low LH was identified and continuing until ovulation triggering. Embryological outcomes and clinical pregnancy rates were retrospectively evaluated.
This cohort included 241 women undergoing their first IVF/ICSI cycle using a GnRH antagonist protocol who had serum luteinizing hormone (LH) levels of 1.2 mIU/mL or higher at both menstrual cycle day 2 and stimulation day 5 (corresponding to menstrual cycle day 6). These patients underwent standard ovarian stimulation without recombinant LH supplementation as part of routine clinical care. Embryological outcomes and clinical pregnancy rates were retrospectively evaluated.
Number of good-quality blastocysts per IVF/ICSI cycle
The primary outcome was the number of good-quality blastocysts obtained per IVF/ICSI cycle. Blastocyst quality was assessed using the Gardner grading system. Good-quality blastocysts were defined as blastocysts with an expansion grade of 4-6 and inner cell mass (ICM) and trophectoderm (TE) grades of AA, AB, or BA. The number of good-quality blastocysts per cycle was compared between women who received LH-guided recombinant LH supplementation and those who did not receive supplementation.
Time frame: At blastocyst assessment, 5-6 days after oocyte retrieval
Clinical pregnancy rate confirmed by transvaginal ultrasonography
The secondary outcome was the clinical pregnancy rate following IVF/ICSI treatment. Clinical pregnancy was defined as the ultrasonographic visualization of one or more gestational sacs. Serum beta-human chorionic gonadotropin (β-hCG) was measured 10 days after blastocyst transfer, followed by transvaginal ultrasonography approximately 2 weeks after biochemical pregnancy confirmation. The clinical pregnancy rate was calculated as the percentage of women with a confirmed clinical pregnancy among all women who underwent embryo transfer in each study group.
Time frame: Approximately 24 days after blastocyst transfer
Ran from Jan 2023 to primary completion in Dec 2023, 11 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stella Maris Women and Children Hospital